Compare Citius Pharmaceuticals Inc (CTXR) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Freshworks Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Freshworks Inc trades at $10.5 (market cap $2.89B). The key difference: Freshworks Inc is far larger — about 197.4× Citius Pharmaceuticals Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FRSH | |
|---|---|---|
Market Cap | $14.64M | $2.89B |
Sector | Health | Technology |
52-Week High | $1.82 | $14.77 |
52-Week Low | $0.53 | $6.88 |
Enterprise Value | $10.86M | $2.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Freshworks (FRSH) trades at $10.83, up 4.54% today, with a bullish technical signal from moving averages. The company shows strong fundamental improvement, with revenue growing from $498M in 2022 to $839M in 2025 and achieving profitability with a net income margin of 20.69%. Recent news highlights AI product launches and a strategic pivot to employee experience, with Q2 2026 earnings due August 4, 2026.
The outlook is positive given consistent revenue growth, high gross margins, and analyst consensus pointing to a 26% upside. Risks include execution of the new strategic focus and competitive pressures in the SaaS sector. The stock presents a value opportunity with a P/E of 17.63, below software industry averages, supported by improving cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
